Business · 06/11/20261 min read
HKEX 2026 Third quarter results
Summary
HKEX 2026 Third quarter results
Original source language: Hong Kong Exchanges and Clearing — News ReleasesOpen original release →
Explore insights
Business insights →Related business signals
6Business · 11/5/2026
Quantinuum reports third quarter 2026 results and increases full-year revenue outlook
Third-quarter Revenue Grew 233% Year Over Year; Raised FY2026 Revenue Outlook Extended Fault Tolerance Industry Leadership with Back-to-Back World Records, Validating Most Credible Path to Universal, Fault-Tolerant...
Read summary →Business · 11/6/2026
Forest fires in Indonesia weigh on forestry, regional growth: BPS
Indonesia's forestry sub-sector contracted 2.52 percent in the third quarter as wildfires weighed on economic ...
Read summary →Business · 11/5/2026
Economist / Indonesia's economy is growing 5.47% in the third quarter of 2026
Jakarta 25 Jammadi 1 1448 H 05 November 2026 VAS revealed official data in Indonesia that the economy achieved 5.47% year-on-year growth in the third quarter of this year, compared to 5.29% during the second quarter.
Read summary →Business · 11/6/2026
AlphaESS, fourth quarter of 2026, BloombergNEF Tier 1 energy storage manufacturer ranked fifth consecutive.
Nandong, China 6 November 2026 — AlphaESS has been recognized as a global Tier 1 energy storage manufacturer again in the 2026 fourth quarter list of BloombergNEF (BloombergNEF, BNEF), reaffirming its established performance and expansion of position on the global large-scale utility market demonstrated by energy storage projects.
Read summary →Business · 11/5/2026
Miami International Holdings reports October 2026 Results of trading
MIAX Exchange Group reports a 16.6% increase in multi-list options ADV YTD PRINCETON, N.J. and MIAMI, Nov. 5, 2026 — Miami International Holdings, Inc.
Read summary →Business · 11/5/2026
Menarini group and liver therapeutics, relapsed pre-treatment therapy, reactive, nonresponsive aggressive B cells, non-hyozycin lymphoma target doping tips ((MEN1703, SEL24) JASPIS-01 clinical secondary first data published by 2026 ASH annual scientific journal
The first clinical data of the l-dapoletic tip single therapy: all available standard treatment options are the first results of a JASPIS-01 clinical secondary study evaluating the kinase inhibitor dapoletictip (dapolsertib, MEN1703) amongst class 1 trajectory PIM/FLT3 targeted at patients with degenerative relapsing, nonresponsive, aggressive B cell non-hypocyte lymphoma (B-NHL).
Read summary →